In this double-blind , placebo-controlled , randomized , multinational phase III trial , @,@ patients with human epidermal growth factor receptor @ ( HER@ ) - negative breast cancer who had not received cytotoxic chemotherapy in the advanced setting were randomly assigned at a two-to-one ratio to receive docetaxel @ mg/m ( @ ) plus ramucirumab @ mg/kg or docetaxel @ mg/m ( @ ) plus placebo once every @ weeks .